‘Plasma first’ approach for detecting epidermal growth factor receptor mutation in advanced non-small cell lung carcinoma

• DOI: 10.1007/s00432-024-05828-w
• Publication Date: 2024-07-27T09:01:25Z
• Authors: Amber Rathor; Prabhat Singh Malik; Pranay Tanwar; Sachin Khurana; Hemavathi Baskarane; Deepam Pushpam; Aruna Nambirajan; Deepali Jain
• Keywords: Concordance; Liquid biopsy; Hematology

Abstract Introduction The treatment approach for recently diagnosed advanced non-small cell lung cancer (NSCLC) with EGFR mutations primarily relies on confirming the tissue diagnosis as non-squamous NSCLC. This routine clinical practice of imposes several barriers and delays in turnaround time (TAT) biomarker testing, significantly delaying to treatment. objective this study is investigate ‘plasma first’ detection mutation stage naïve NSCLC patients. Methods We prospectively collected blood samples patients radiological suspicion prior obtaining biopsy. Plasma cfDNA was tested using two different methods. compared sensitivity TAT liquid biopsy Results In total, we analyzed plasma cell-free DNA (cfDNA) 236 suspected having mutations. observed a notably shorter 3 days, which quicker 12-day ( p < 0.05). ddPCR method had 82.8%, higher than 66.34% ARMS-PCR. current also highlights that there no significant difference outcome whether treated based only or (median progression-free survival 11.56 vs. 11.9 months; = 0.94). Conclusions Utilizing strategy, given its time, strong positive concordance comparable outcomes biopsy, emerges highly specific reliable detecting advanced-stage